Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IQ0Z
|
||||
| Former ID |
DCL001072
|
||||
| Drug Name |
GSK1070916
|
||||
| Synonyms |
GSK-1070916
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B] | Phase 1 | [1], [2] | ||
| Company |
GlaxoSmith-Kline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C30H33N7O
|
||||
| InChI |
InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)
|
||||
| InChIKey |
QTBWCSQGBMPECM-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
103748127, 104150130, 109692758, 120907915, 125748893, 134339469, 134347882, 135315559, 135686172, 135686173, 135686194, 135686195, 136348839, 136349579, 136367710, 137130830, 139905068, 144116024, 152258884, 152344275, 160647733, 162011765, 162038111, 164194002, 165238064, 165246679, 174006386, 174531617, 177748955, 180371646, 198945210, 203088743, 223258873, 223685850, 224105858, 230247385, 242979888, 251963082, 251971181, 252166570, 252215499, 252359510, 252451734
|
||||
| Target and Pathway | |||||
| Target(s) | Aurora kinase B | Target Info | Modulator | [3] | |
| Aurora protein kinase | Target Info | Modulator | [3] | ||
| KEGG Pathway | Oocyte meiosis | ||||
| Pathway Interaction Database | Aurora B signaling | ||||
| Signaling by Aurora kinases | |||||
| Aurora C signaling | |||||
| FOXM1 transcription factor network | |||||
| Aurora A signaling | |||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate Formins | |||||
| Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
| WikiPathways | Mitotic Metaphase and Anaphase | ||||
| Mitotic Prometaphase | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway | |||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8358). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032133) | ||||
| REF 3 | J Med Chem. 2010 May 27;53(10):3973-4001.Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.